翰宇药业：预计2025年上半年净利润同比扭亏为盈

Core Viewpoint - Hanyu Pharmaceutical (300199) expects a net profit of 142 million to 162 million yuan in the first half of 2025, a significant turnaround from a loss of 10.36 million yuan in the same period last year, indicating a strong recovery in profitability driven by multiple factors [1] Financial Performance - The company is projected to achieve a net profit of 142 million to 162 million yuan in H1 2025, compared to a loss of 10.36 million yuan in H1 2024, marking a year-on-year turnaround [1] - The anticipated profit reflects a robust growth trajectory and improved financial health for the company [1] Market Dynamics - The growth in global market demand is a key driver behind the company's improved financial outlook [1] - The approval and subsequent sales of liraglutide injection, submitted to the U.S. Food and Drug Administration on December 23, 2024, are expected to contribute positively to revenue [1] - Continuous growth in raw material exports has also played a significant role in enhancing the company's market position [1] Operational Efficiency - The company has maintained a high operating profit margin in its international business, which has further boosted overall profitability [1] - Strict cost control measures have been implemented, contributing to the improved financial performance [1]